MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is extremely pleased to announce that Major General (Ret.) Gale S. Pollock, CRNA, FACHE, FAAN, has agreed to join Covalon’s Board of Directors.
Major General Pollock is a two-star General who retired in 2008 after 36 years of service in the U.S. Army. She held the position of Acting Surgeon General of the U.S. Army. Major General Pollock was the first woman and the first non-physician to serve in this role in any of the military services of the United States. In this capacity, Major General Pollock was responsible for a worldwide 24/7 medical operation with a budget of $9.7 billion and a staffing complement of approximately 6500 people.
Major General Pollock said, “I am very excited to join Covalon’s Board of Directors. Covalon has proven that it has a number of unique infection control and advanced wound care technologies that are just beginning to gain traction in the global marketplace. At the same time, Covalon has a number of extremely exciting technologies in the lab waiting to be commercialized.”
"Covalon is very fortunate to have someone of Major General Pollock’s stature join our Board of Directors," said Brian Pedlar, Covalon's Chief Executive Officer. "Gale has a very impressive career within the military as well as having become a champion of several extremely important initiatives since leaving the United States Army. Her yeas of leadership working within military and non-military healthcare systems will be an invaluable benefit to Covalon.”
While in the United States Army, Major General Pollock served as the Commander of the United States Army Medical Command. Major General Pollock was also the 22nd Chief of the Army Nurse Corps.
Major General Pollock serves on multiple advisory boards and is the President of Pollock Associates, LLC. She is a Fellow in the American College of Healthcare Executives, the American Academy of Nursing and the National Board of Corporate Directors. In 2008, Major General Pollock established the Louis J. Fox Center for Vision Restoration and was an associate professor at the University of Pittsburgh Schools of Medicine and Nursing. In 2011, Major General Pollock became a Harvard University Fellow in their “Advanced Leadership Initiative” program.
Major General Pollock has a Master’s Degree in Business, a Master’s Degree in Healthcare Administration and a Master’s Degree in National Security and Strategy. She received an Honorary Doctorate from the University of Maryland.
General Pollock’s appointment to Covalon’s Board of Directors is subject to TSX approval.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
